DiscoverThe Lancet in conversation withPresented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma

Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma

Update: 2025-12-07
Share

Description

Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.

Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments 
loading
In Channel
ASCO 2025 Debrief

ASCO 2025 Debrief

2025-06-1114:44

Previewing ASCO 2025

Previewing ASCO 2025

2025-05-3004:54

loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma

Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma

The Lancet Group